Quetiapine in relapsing schizophrenia: Clinical efficacy and effect on monoaminergic parameters

Acta Neuropsychiatrica

Volumn 15, Issue 3, 2003, Pages 133-139

  Van der Heijden, F M M A ^a   Verhoeven, W M A ^a,b   Fekkes, D ^b   Sijben, A E S ^a   Tuinier, S ^a  

^a VINCENT VAN GOGH INSTITUTE FOR PSYCHIATRY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Amino acids; Monoamines; Quetiapine; Schizophrenia

Indexed keywords

AMINO ACID; MONOAMINE; QUETIAPINE; SEROTONIN; TRYPTOPHAN; TYROSINE;

ADOLESCENT; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; FLU LIKE SYNDROME; HEART PALPITATION; HUMAN; LIVER FUNCTION TEST; MALE; MONOAMINERGIC SYSTEM; RATING SCALE; RELAPSE; RESTLESSNESS; SCHIZOPHRENIA; SCHOOL CHILD; SEDATION; SIDE EFFECT; SLEEP DISORDER; SWEATING; SYMPTOMATOLOGY; VERTIGO; WEIGHT GAIN;

EID: 0038657606     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1601-5215.2003.00025.x     Document Type: Article

References (39)

1. BALDESSARINI RJ, FRANKENBURG FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324:746-754.
2. VERHOEVEN WMA, DOESBURG WH, SNOEJ R, RUTGERS AJMP, VAN DONGEN PHM. Efficacy of clozapine in treatment-resistant psychosis and neuroleptic sensitivity; results of the Dutch open multi-center project. Eur Psychiatry 1992;7:77-84.
3. ARNT J, SKARSFELDT T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacol 1998;18:63-101.
4. GOLDSTEIN JM, ARVANITIS LA. ICI 204,636 (Seroquel): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev 1995;1:50-73.
5. GUNASEKARA NS, SPENCER CM. Quetiapine, a review of its use in schizophrenia. CNS Drugs 1998;9:325-340.
6. GOLDSTEIN JM. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today 1999;35:193-210.
7. FABRE LF, ARVANITIS L, PULTZ J, JONES VM, MALICK JB, SLOTNICK VB. ICI 204-636, a novel, atypical antipsychotic. early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995;17:366-378.
8. BORISON RL, ARVANITIS LA, MILLER BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-169.
9. SMALL JG, HIRSCH SR, ARVANITIS LA, MILLER BG, LINK CG. Quetiapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo. Arch General Psychiatry 1997;54:549-557.
10. MEATS PH. Quetiapine (Seroquel);an effective and well-tolerated atypical antipsychotic. Int J Psychiatry Clin Pract 1997;1:231-239.
11. ARVANITIS LA, MILLER BG. Multiple fixed doses of 'Seroquel' (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246.
12. COPOLOV DL, LINK CG G, KOWALCYK B. A multicenter, double-blind, randomized comparison of quetiapine (ICI 204-636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 2000;30:95-105.
13. KASPER S, TAUSCHER J, HEIDEN A. Quetiapine: efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol 2001;11:S405-413.
14. SHARMAT T. Quetiapine, efficacy in different domains. Eur Neuropsychopharmacol 2001;11:S385-390.
15. PEUSKENS J, LINK CG G. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273.
16. McMANUS DQ, ARVANITIS LA, KOWALCYK BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999;60:292-298.
17. McCONVILLE BJ, ARVANITIS LA, THYRUM PT, YEH C, WILKINSON LA, CHANEY RO, FOSTER KD, SORTER MT, FRIEDMAN LM, BROWN KL, HEUBI JE. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000;61: 252-260.
18. TAYLOR DM, McASKILL R. Atypical antipsychotics and weight gain, a systematic review. Acta Psychiatr Scand 2000;101:416-432.
19. MEYER JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001;21:369-374.
20. FERNANDEZ HH, FRIEDMAN JH, JACQUES C, ROSENFELD M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999;14:484-487.
21. TARGUM SD, ABBOTT JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000;20:54-60.
22. BRANDSTÄDTER D, OERTEL WH. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 2002;58:160-161.
23. VERHOEVEN WMA, RIJN-VAN DEN MEIJDENBERG JCC, HOFMA E, TUINIER S, FEKKES D, PEPPLINKHUIZEN L. Aminoacids, norharman and serotonergic parameters in schizophrenia; clinical and biochemical effects of treatment with risperidone. New Trends Exp Clin Psychiatry 1997;13:117-126.
24. MOOREN R, VERHOEVEN WMA, TUINIER S, VAN DEN BERG YW MM, FEKKES D, PEPPLINKHUIZEN L. Olanzapine in schizophrenia;effects on psychotic symptomatology and serotonergic parameters. Eur J Psychiatry 2001;15:91-100.
25. DOORAKKERS MCH VERHOEVEN WMA, TUINIER S, VAN DEN BERG YWMM, FEKKES D, PEPPLINKHUIZEN L. Psychopathology, serotonergic parameters and sertindole. Results of a preliminary study in schizophrenia. New Trends Exp Clin Psychiatry 2000;17:25-30.
26. FEKKES D, VAN DALEN A, EDELMAN M, VOSKUILEN A. Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated derivatization with o-phtaldialdehyde. J Chromatogr B Biomed Appli 1995;669:177-186.
27. MELTZER HJ, MAES M, LEE MA. The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine. Psychopharmacology (Berl) 1993;112(Suppl. 1):95-104.
28. SUMIYOSHI T, HASEGAWA M, JAYATHILAKE K, MELTZER HY. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry Res 1997;69:113-121.
29. KOREEN AR, LIEBERMAN J, ALVIR J, MAYERHOFF D, LOEBEL A, CHAKOS M, AMIN F, COOPER T. Plasma homovanillic acid levels in first-episode schizophrenia. Arch General Psychiatry 1994;51:132-138.
30. GARVER DL, HOLCOMB JA, CHRISTENSEN JD. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. J Clin Psychiatry 2000;61:964-972.
31. FEKKES D, PEPPLINKHUIZEN L, VERHEIJ R, BRUINVELS J. Abnormal plasma levels of serine, methionine, and taurine in transient polymorphic psychosis. Psychiatry Res 1994;51:11-18.
32. FEKKES D, PEPPLINKHUIZEN L. Amino acid studies in transient acute polymorphic psychosis. Amino Acids 1997;12:107-117.
33. VAN DER HEIJDEN FMMA, TUINIER S, PEPPLINKHUIZEN L, VAN PRAAG HM, VERHOEVEN WMA. Beyond the mainstream: the heuristic value of the cycloid psychosis. Eur J Psychiatry 2002;16:15-26.
34. FLYCKT L, VENIZELOS N, EDMAN G, BJERKENSTEDT L. HAGENFELDTL, WIESEL FA. Aberrant tyrosine transport across the cell membrane in patients with schizophrenia. Arch General Psychiatry 2001;58:953-958.
35. MIDDLETON FA, MIRNICS K, PIERRI JN, LEWIS DA, LEVITT P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 2002;22:2718-2729.
36. TORTORELLA A, MONTELEONE P, FABRAZZO M, VIGGIANO A, DE LUCA L, MAJ M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiol 2001;44:167-171.
37. WIESELGREN IM, LINDSTROM LH. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiatry Res 1998;81:101-110.
38. CARL GF, BROGAN MP, YOUNG BK. Is plasma serine a marker for psychosis? Biol Psychiatry 1991;31: 1130-1135.
39. RAO ML, GROSS G, STREBEL B, BRAUNIG P, HUBER G, KLOSTERKOTTER J. Serum amino acids, central monoamines, and hormones in drug-naïve, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res 1990;34:243-257.